Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daewon Pharmaceutical Co., Ltd. (003220:KRX), powered by AI.
Daewon Pharmaceutical Co., Ltd. is currently trading at ₩11,240. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Daewon Pharmaceutical Co., Ltd. on Alpha Lenz.
Daewon Pharmaceutical Co., Ltd.'s P/E ratio is -182.7.
“Daewon Pharmaceutical Co., Ltd. trades at a P/E of -182.7 (undervalued) with modest ROE of -0.5%.”
Ask for details →Daewon Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company primarily engaged in the research, development, and manufacture of pharmaceutical products. Founded in 1958, the company has established itself in the healthcare industry by offering a diverse portfolio that includes prescription medicines, over-the-counter drugs, and nutritional supplements. Its product lineup addresses various therapeutic areas such as cardiovascular diseases, oncology, and pain management, catering to a wide demographic. Daewon Pharmaceutical leverages advanced biotechnology and rigorous quality controls in its manufacturing processes, ensuring high standards in product efficacy and safety. As a significant player in the pharmaceutical sector, the company contributes to public health by providing essential medical solutions, enhancing patient care, and supporting sustainable health systems. It operates with a commitment to innovation and regulatory compliance, positioning itself as a trusted partner in the medical and healthcare markets worldwide.
“Daewon Pharmaceutical Co., Ltd. trades at a P/E of -182.7 (undervalued) with modest ROE of -0.5%.”
Ask for details →Daewon Pharmaceutical Co., Ltd. (ticker: 003220) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,283 employees. Market cap is $252.1B.
The current price is ₩11,240 with a P/E ratio of -182.71x and P/B of 0.95x.
ROE is -0.51% and operating margin is 0.58%. Annual revenue is $605.4B.